3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
2
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
pembrolizumab
49
Nivolumab
22
Cyclophosphamide
20
fludarabine
13
Paclitaxel
9
Ipilimumab
9
atezolizumab
8
aldesleukin
8
Specimen Handling
8
Interleukin-2
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Docetaxel
6
Biopsy
6
cemiplimab
5
fludarabine phosphate
4
durvalumab
4
Taxes
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
poly ICLC
3
epacadostat
3
X-Rays
3
Leucovorin
3
Injections
3
Immunoglobulin G
3
Filgrastim
3
Cisplatin
3
CTLA-4 Antigen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
trastuzumab deruxtecan
×
Gynecologic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled